Wu W, Liu M, Geng JJ, Wang M. Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections. World J Clin Cases 2021; 9(34): 10549-10556 [PMID: 35004986 DOI: 10.12998/wjcc.v9.i34.10549]
Corresponding Author of This Article
Mei Wang, MHSc, Attending Doctor, Laboratory Medicine, Bejing Tongren Hosptial, Capital Medical University, No. 2 West Ring South Road, Beijing 100176, China. wmeimeiw@163.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 6, 2021; 9(34): 10549-10556 Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10549
Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections
Wei Wu, Min Liu, Jia-Jing Geng, Mei Wang
Wei Wu, Jia-Jing Geng, Mei Wang, Laboratory Medicine, Bejing Tongren Hospital, Capital Medical University, Beijing 100176, China
Min Liu, Department of General Practice, The Community Health Services Center in Lumen, Beijing 100080, China
Author contributions: Wu W and Wang M designed the research study; Liu M performed the research; Geng JJ analyzed the data and wrote the manuscript.
Institutional review board statement: The study was reviewed and approved by the Beijing Tongren Hospital, Capital Medical University Institutional Review Board (Approval No. TRECKY2020-100).
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: No conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mei Wang, MHSc, Attending Doctor, Laboratory Medicine, Bejing Tongren Hosptial, Capital Medical University, No. 2 West Ring South Road, Beijing 100176, China. wmeimeiw@163.com
Received: July 28, 2021 Peer-review started: July 28, 2021 First decision: August 19, 2021 Revised: August 24, 2021 Accepted: October 14, 2021 Article in press: October 14, 2021 Published online: December 6, 2021
ARTICLE HIGHLIGHTS
Research background
Vancomycin and teicoplanin are important drugs in the clinical treatment of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis lung infections.
Research motivation
Single-drug treatment of lung infections is not effective.
Research objectives
We want to compare the therapeutic effects of conventional antibacterial therapy (vancomycin only) and vancomycin plus teicoplanin.
Research methods
We selected 86 patients with methicillin-resistant Staphylococcus aureus (MRSA) or Staphylococcus epidermidis lung infections and divided them into a study group and a control group, with 43 cases in each group.
Research results
The study group was more effective than the control group.
Research conclusions
The combined teicoplanin/vancomycin treatment of patients with pulmonary methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis infections resulted in improved clinical responses.
Research perspectives
The combined application of antibacterial drugs increases the cure rate of the disease.
